Abstract:Severe congenital neutropenia (SCN) is caused by germline mutations, most commonly in ELANE , impacting neutrophil maturation and leading to high risk of life-threatening infections. Most patients with ELANE- mutant SCN can achieve safe neutrophil counts with chronic Granulocyte-Colony Stimulating Factor (G-CSF). However, up to 10% of patients have neutropenia refractory to G-CSF and require allogeneic stem cell transplant. Traditional conditioning for these patients includes busulfan and cyclophosphamide which is associated with significant toxicities. We present five patients with SCN without myeloid malignancy transplanted using a reduced toxicity regimen of busulfan, fludarabine and thymoglobulin. 5 pediatric patients with SCN underwent matched sibling donor bone marrow transplant (MSD-BMT) between 2014-2022 on or per CHP14BT057 (NCT02928991), a prospective, single center trial testing elimination of cyclophosphamide from conditioning in pediatric patients with single lineage inherited BMF syndromes. All patients had MSDs and no evidence of MDS. Conditioning consisted of PK-adjusted busulfan, fludarabine, and thymoglobulin, with calcineurin inhibitor and mycophenolate mofetil GVHD prophylaxis. With median follow-up of 48.4 months, overall and event-free survival were 100%. There was no acute GVHD and one instance of chronic limited GVHD. Patients exhibited >95% donor myeloid chimerism at 5 years post-BMT. Two patients experienced CMV reactivation without end-organ disease, and no other viral reactivation or significant infections occurred. MSD-BMT with reduced toxicity myeloablation for SCN provides excellent outcomes while minimizing toxicity. These data suggest that busulfan, fludarabine, and ATG can be considered an efficacious, low-toxicity standard of care regimen for patients with SCN undergoing MSD-BMT.

[Gene Mutation and Acute Leukemia Transformation of Severe Congenital Neutropenia- Review].

Mechanisms of leukemic transformation in congenital neutropenia

Severe congenital neutropenia caused by ELANE gene mutation: A case report and literature review

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Successful Bone Marrow Transplantation in a Patient with Acute Myeloid Leukemia Developed from Severe Congenital Neutropenia Using Modified Chemotherapy and Conditioning Regimen for Leukemia

Research of gene mutation in acute myeloid leukemia: development and prospect

Novel ELANE Gene Mutation in a Newborn with Severe Congenital Neutropenia: Case Report and Literature Review.

Altered Functions of Neutrophils in Two Chinese Patients With Severe Congenital Neutropenia Type 4 Caused by G6PC3 Mutations

Impact of different genetic mutations on granulocyte development and G-CSF responsiveness in congenital neutropenia

Congenital neutropenia: disease models guiding new treatment strategies

Clinical relevance of SCN and CyN induced by ELANE mutations: a systematic review

Research progress of additional pathogenic mutations in chronic neutrophilic leukemia

Acute lymphoblastic leukemia following severe congenital neutropenia or de novo ALL?

CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia

[Research Progress on Genes Associated with Transformation of Myelodysplastic Syndromes to Acute Myeloid Leukemia].

Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis

Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia

Neutrophil Elastase Defects in Congenital Neutropenia

Reduced toxicity matched sibling bone marrow transplant results in excellent outcomes for severe congenital neutropenia

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Role of Gene Mutations in Acute Myeloid Leukemia: A Review Article